FDA Clearance Tracker · K221349
XPER Technology PREMIUM Pro Blood Glucose Monitoring System
Last checked: Nov 20, 2026Latest source record: Nov 19, 2024 (this decision)Source: openFDAMethods & limitations
Decided
Nov 19, 2024
Substantially Equivalent
Time to decision
925 days
Received May 9, 2022. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Dual Track
Device class
Class II
The decision
- FDA number
- K221349
- Device name
- XPER Technology PREMIUM Pro Blood Glucose Monitoring System
- Applicant
- Taidoc Technology Corporation
- Applicant location
- New Taipei City, TW
- Received
- May 9, 2022
- Decided
- Nov 19, 2024
- Decision
- Substantially Equivalent
- Submission type
- Dual Track
Device type
- Device class
- Class II
- Regulation
- 21 CFR 862.1345
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code PZI. The earliest in FDA's data is K132121, decided Sep 24, 2014.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K221349
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Taidoc Technology Corporation
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K201037 · Decided Jun 16, 2022 · 787 days after receipt
Device type: System, Test, Blood Glucose, Over The Counter (NBW) · Laboratory Medicine & Pathology
K200946 · Decided Apr 5, 2022 · 727 days after receipt
Device type: Continuous Measurement Thermometer (FLL) · Hospital Medicine & Nursing
K190579 · Decided Jun 4, 2019 · 90 days after receipt
Device type: System, Test, Blood Glucose, Over The Counter (NBW) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.